Assertio Therapeutics (ASRT) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Assertio Therapeutics Announces First-Quarter 2019 Financial Results
May 8, 2019 4:02 PM EDT-- Reports Neurology Franchise Net Sales of $26.3 million --
-- Commercialization Agreement Revenues of $30.9 million --
-- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance --
-- Significant Debt Reduction --
LAKE FOREST, Ill., May 08, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
First-Quarter Financial Highlights:(unaudited)
... More